Also known as: Nasdaq, NASDAQ
Nasdaq, Inc. is a U.S.-based multinational financial services company that operates stock exchanges and market infrastructure platforms. Founded in 1971 and headquartered in New York City, it owns and operates the Nasdaq exchange among others. The company is publicly traded on Nasdaq under NDAQ.
Greenwich LifeSciences received a second Nasdaq notice for late filing of its Form 10-Q, following a prior notice for a late Form 10-K. The company's stock continues trading on the Nasdaq Capital Market while it works to file the overdue reports.
Compugen said it will release fourth quarter and full year 2025 results on March 2, 2026, and present at the Needham Virtual Healthcare Conference on April 13. The company also outlined its Phase 1 and Phase 3 immuno-oncology pipeline programs.
Immunic reported first-quarter 2026 results and said a $200 million upfront private placement is expected to fund phase 3 ENSURE trials in relapsing MS. The financing could provide up to $400 million in gross proceeds.
argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.
Dianthus, Taysha and aTyr disclosed inducement equity grants for newly hired employees under Nasdaq Listing Rule 5635(c)(4), detailing share awards, vesting schedules and exercise prices.
Silo Pharma said the Japan Patent Office issued a Notice of Allowance for a patent application covering SPC-15, its intranasal PTSD therapeutic. The allowed application covers composition and method claims, with formal patent grant expected to follow.
Elicio Therapeutics granted inducement stock options to new employees, with one grant of 1,600 options at $12.16 per share and another of 30,300 options at $8.59 per share. The clinical-stage biotech company is developing novel immunotherapies targeting mKRAS-positive cancers, with its ELI-002 program showing promising Phase 1 results including 16.3-month median recurrence-free survival.
Gilead Sciences has agreed to buy immunotherapy cancer biotech Arcellx in a deal worth $7.8 billion, deepening its bet on cancer immunotherapy and its existing partnership with the company.
Medtronic's diabetes unit MiniMed is seeking up to $7.86 billion valuation in its U.S. IPO while cutting 81 jobs at its Northridge facility ahead of the planned separation into a standalone publicly traded company.
Trinity Biotech plc received two separate non-compliance notices from Nasdaq in February 2026 for failing to meet minimum bid price and market value requirements, with 180-day periods to regain compliance or face potential delisting.
